Many phase 3 trials for biologic therapies including TNF inhibitors, IL23 inhibitors, and IL17 inhibitors have included secondary outcomes including symptoms of depression and anxiety apart from quality of life. The gene discussed is IL17A; the disease is depressive disorder.